Compounded blend: BPC-157 + GHK-Cu + TB-500
A combination product marketed for skin rejuvenation and whole-body recovery, pairing two regenerative peptides with the copper peptide.
| Class / type | Compounded blend: BPC-157 + GHK-Cu + TB-500 |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
Proposed synergy: GHK-Cu drives collagen/angiogenesis; BPC-157 supports repair; TB-500 promotes cell migration/vascular growth.
Skin tone/texture 'glow', injury and connective-tissue recovery, reduced inflammation.
Combines complementary mechanisms; users report skin/recovery improvement in ~2-8 wks. NOTE: no controlled trials on the blend itself.
Carries every risk of its individual ingredients, plus combination-specific unknowns (no studies test the three together for safety or interactions). Two of its ingredients, BPC-157 and TB-500, heal partly by growing new blood vessels and moving cells around - the same processes a tumor needs to grow and spread - so there is a theoretical, unproven concern the blend could feed a cancer a person does not yet know they have. That risk matters most for anyone with a cancer history. It is not FDA-approved, and compounded products can vary in purity and sterility.
'Two-in-one' appeal - visible skin improvement plus recovery in one blend.
NOT FDA-approved. Its BPC-157 and TB-500 components were recommended for 503A compounding by an FDA advisory panel in July 2026, but that vote is advisory and not yet final. Sold research-use-only / via compounding. Verify.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.